Mesoblast now expects to release Ryoncil ruling on Monday
Mesoblast is in a trading halt, but does not expect to announce the Federal Drugs and Administration's on Ryoncil on Monday to the General Public. The approval of the stem cell treatment to treat pediatric graft-versus-host disease is transformative for the company making it the leading company in stem cell technologies. Already successful in Europe and Japan, Mesoblast is now making arrangements with development, marketing and distribution with the Office of Science of Science and technology Policy (OSTP). Stem cell technology has attracted the interest of the International Health and Science business Community and Governments at large. Following Mesoblast's lead important positive news from the Scientific Community by three other major leading stem cell development companies, Immutep Limited, Orthocell Limited and Neuren Pharmaceuticals are now pending.
Mesoblast now expects to release Ryoncil positive ruling on Monday
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.12 |
Change
0.020(1.82%) |
Mkt cap ! $1.370B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.21 | $1.07 | $20.52M | 18.00M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 52967 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 42113 | 7 |
View Market Depth
| Last trade - 11.56am 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.11 |
Change
0.020 ( 0.65 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.21 | $1.07 | 3394944 | ||
| Last updated 12.15pm 02/05/2024 ? | |||||
| MSB (ASX) Chart |